Answers are grounded in this paper and cite their sources.
The present study is a comparative single-dose, open-label, randomized, three-treatment, six-sequence, threeperiod, crossover, in vivo study to determine the bioequivalence of two test products: Test 1; Sildenamax (Sildenafil 100 mg), Test 2; Satenafil (Sildenafil 100 mg) manufactured by Organo for Pharmaceutical and Chemical Industries, versus VIAGRA (Sildenafil 100 mg) manufactured by Pfizer Egypt, USA and its Subsidiary in UK after a single oral dose administration given to healthy adult volunteers under fasting conditions. The subjects who conform to the study entry criteria were dosed according to a randomization schedule. Furthermore, the study was designed and completed according to the good clinical and laboratory practices.
No takes yet. Share an insight, caveat, or question.
HA et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: